Intramyocardial injection of allogenic bone marrow-derived mesenchymal stem cells without immunosuppression preserves cardiac function in a porcine model of myocardial infarction
- PMID: 16382259
- DOI: 10.1177/107424840501000403
Intramyocardial injection of allogenic bone marrow-derived mesenchymal stem cells without immunosuppression preserves cardiac function in a porcine model of myocardial infarction
Abstract
Background: We investigated the efficacy of directly injected allogenic bone marrow-derived mesenchymal stem cells in improving left ventricular function in a porcine model of myocardial infarction.
Methods: Left ventricular infarction was created in 16 adult Yorkshire pigs by coil embolization and thrombotic occlusion distal to the second diagonal artery. One month after myocardial infarction was induced, the animals were randomized to either direct injection of allogenic mesenchymal stem cells or sham treatment (culture medium). Allogenic bromodeoxyuridine-labeled mesenchymal stem cells (2 +/- 0.1 x 10(8)) were directly injected into the infarct and peri-infarct areas during an open chest procedure. No immunosuppressive therapy was used. The left ventricular function was measured using serial biplane left ventricular angiography at baseline, 30, 60, and 90 days before sacrifice. Mesenchymal stem cells were localized using bromodeoxyuridine, and differentiation of mesenchymal stem cells was assessed by confocal microscopic colocalization of bromodeoxyuridine with immunofluorescent antibodies specific for cardiomyocytes (troponin I and MF-20) and endothelial cells (von Willebrand factor).
Results: Mesenchymal stem cells labeled with bromodeoxyuridine engrafted the peri-infarct zone and colocalized with both cardiomyocyte-specific and endothelial cell-specific immunofluorescence. No intramyocardial bromodeoxyuridine was observed in sham-treated animals. At the time of the mesenchymal stem cell injection 30 days after myocardial infarction, the left ventricular ejection fraction (LVEF) was 58% +/- 3% in mesenchymal stem cell-treated pigs and 56% +/- 2% in sham-treated pigs (P = NS). LVEF deteriorated progressively thereafter in untreated pigs (8.5% and 10.5% decline at 60 days and 90 days after myocardial infarction, respectively), but was preserved in mesenchymal stem cell-treated pigs (2.1% increase and -2.0% decline at 60 and 90 days post-MI respectively) (P < .05).
Conclusions: Direct intramyocardial injection of mesenchymal stem cells results in successful intramyocardial engraftment and differentiation into cardiomyocytes and endothelial cells and preserves left ventricular function after myocardial infarction in pigs.
Similar articles
-
Intravenous mesenchymal stem cell therapy early after reperfused acute myocardial infarction improves left ventricular function and alters electrophysiologic properties.Int J Cardiol. 2006 Aug 10;111(2):231-9. doi: 10.1016/j.ijcard.2005.07.036. Epub 2005 Oct 24. Int J Cardiol. 2006. PMID: 16246440
-
Left ventricular functional recovery with percutaneous, transvascular direct myocardial delivery of bone marrow-derived cells.J Heart Lung Transplant. 2005 Sep;24(9):1385-92. doi: 10.1016/j.healun.2004.10.010. J Heart Lung Transplant. 2005. PMID: 16143261
-
Immediate intramyocardial bone marrow-derived mononuclear cells implantation in minipig myocardium after permanent coronary artery ligation: magnetic resonance imaging with histopathologic and immunochemical correlation.Invest Radiol. 2011 Aug;46(8):495-503. doi: 10.1097/RLI.0b013e318214a63f. Invest Radiol. 2011. PMID: 21427591
-
Rational transplant timing and dose of mesenchymal stromal cells in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials.Stem Cell Res Ther. 2017 Jan 28;8(1):21. doi: 10.1186/s13287-016-0450-9. Stem Cell Res Ther. 2017. PMID: 28129790 Free PMC article.
-
A brief review: the therapeutic potential of bone marrow mesenchymal stem cells in myocardial infarction.Stem Cell Res Ther. 2017 Nov 2;8(1):242. doi: 10.1186/s13287-017-0697-9. Stem Cell Res Ther. 2017. PMID: 29096705 Free PMC article. Review.
Cited by
-
Exosomes Derived from Human Umbilical Cord Mesenchymal Stem Cells Relieve Acute Myocardial Ischemic Injury.Stem Cells Int. 2015;2015:761643. doi: 10.1155/2015/761643. Epub 2015 May 27. Stem Cells Int. 2015. PMID: 26106430 Free PMC article.
-
Current Status and Limitations of Myocardial Infarction Large Animal Models in Cardiovascular Translational Research.Front Bioeng Biotechnol. 2021 Apr 29;9:673683. doi: 10.3389/fbioe.2021.673683. eCollection 2021. Front Bioeng Biotechnol. 2021. PMID: 33996785 Free PMC article. Review.
-
Research Advancements in Porcine Derived Mesenchymal Stem Cells.Curr Stem Cell Res Ther. 2016;11(1):78-93. doi: 10.2174/1574888x10666150723145911. Curr Stem Cell Res Ther. 2016. PMID: 26201864 Free PMC article. Review.
-
Biomechanical Screening of Cell Therapies for Vocal Fold Scar.Tissue Eng Part A. 2015 Sep;21(17-18):2437-47. doi: 10.1089/ten.TEA.2015.0168. Epub 2015 Jul 22. Tissue Eng Part A. 2015. PMID: 26119510 Free PMC article.
-
Therapeutic potential of mesenchymal stem cells in regenerative medicine.Stem Cells Int. 2013;2013:496218. doi: 10.1155/2013/496218. Epub 2013 Mar 19. Stem Cells Int. 2013. PMID: 23577036 Free PMC article.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous